FOXO4-DRI
Experimental senolytic — the narrowest margin on this list
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Synthetic peptide studied as a senolytic: a compound intended to eliminate senescent cells, those old, damaged cells that stop dividing but do not die, and start releasing inflammatory signals into the neighboring tissue. It is among the compounds with the least human data in this entire reference.
Quick reference
- Target
- Disrupts the FOXO4-p53 interaction so that p53 triggers apoptosis in senescent cells.
- Evidence level
- Only mouse and cell studies. No human trial (June 2026).
- Published protocol
- Mouse: 5 mg/kg intraperitoneal, repeated for weeks (Baar et al., 2017).
- Status
- Not approved. Use restricted to research.
Dose reference
| Week | Daily dose |
|---|---|
| Weeks 1–4 | 250 mcg |
| Weeks 5-8 | 375 mcg |
| Weeks 9-12 | 500 mcg |
| Weeks 13-16 | 500 mcg |
FOXO4-DRI Reconstitution Guide
| Draw (units) | Volume | Amount delivered |
|---|---|---|
| 7.5 units | 0.075 mL | about 0.25 mg (250 mcg) |
| 10 units | 0.10 mL | about 0.33 mg (333 mcg) |
| 11.25 units | 0.1125 mL | about 0.375 mg (375 mcg) |
| 15 units | 0.15 mL | about 0.5 mg (500 mcg) |
| 30 units | 0.30 mL | about 1.0 mg (1,000 mcg) |
Expected timeline
| Window | What is proposed to happen |
|---|---|
| Hours | Peptide enters circulation; competes with FOXO4 for p53 in senescent cells. |
| 1-3 days | Freed p53 reaches mitochondria; senescent cells begin apoptosis. |
| 3-14 days | Immune system clears apoptotic debris; SASP inflammatory signaling declines. |
| 2-6 weeks | Tissue microenvironment improves in animal models as inflammation drops. |
FOXO4-DRI vs Other Senolytics
| Option | Type | Human trial stage |
|---|---|---|
| FOXO4-DRI | D-retro-inverso peptide | None (preclinical only) |
| Dasatinib + Quercetin (D+Q) | Small-molecule drug + flavonoid | Early human trials (for example, in Alzheimer's) |
| Navitoclax | BCL-2 family inhibitor | Later-stage trials (e.g., myelofibrosis) |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.